medication insulin pharmaceutical preparation protein hormone insulin used treat high blood conditions include type diabetes type diabetes gestational diabetes complications diabetes diabetic ketoacidosis hyperosmolar hyperglycemic insulin also used along glucose treat hyperkalemia high blood potassium typically given injection skin forms may also used injection vein various types insulin suitable various time spans types often called insulin broad sense although precise sense insulin identical naturally occurring molecule whereas insulin analogues slightly different molecules allow modified time action world health organizations list essential regular human insulin commonly prescribed medication united states million insulin made pancreas pigs human versions made either modifying pig versions recombinant using mainly e coli saccharomyces comes three main types regular insulin intermediateacting neutral protamine hagedorn nph insulin longeracting insulin insulin first used medication canada charles best frederick banting chronology key milestones history medical use insulin details discovery extraction purification clinical use synthesis insulin see insulin insulin used treat number diseases including diabetes acute complications diabetic ketoacidosis hyperosmolar hyperglycemic states also used along glucose treat high blood potassium levels use pregnancy relatively safe insulin formerly used psychiatric treatment called insulin shock side effects hypoglycemia low blood sugar hypokalemia low blood potassium allergic allergy insulin affected people reactions due insulin preservatives added insulin zinc protamine metacresol reactions type hypersensitivity reactions rarely cause anaphylaxis suspected allergy insulin confirmed skin prick testing patch testing occasionally skin biopsy first line therapy insulin hypersensitivity reactions include symptomatic therapy antihistamines affected persons switched preparation contain specific agent reacting undergo cutaneous adverse effects side effects may include pain skin changes sites injection repeated subcutaneous injection without site rotation lead lipohypertrophy amyloidomas manifest firm palpable nodules early initiation insulin therapy longterm management conditions type diabetes would suggest use insulin unique benefits however insulin therapy need gradually raise dose complexity regimen well likelihood developing severe hypoglycemia many people doctors hesitant begin insulin therapy early stage disease many obstacles associated health behaviors also prevent people type diabetes mellitus starting intensifying insulin treatment including lack motivation lack familiarity experience treatments time restraints causing people high glycemic loads extended periods time prior starting insulin therapy managing side effects associated longterm early routine use insulin type diabetes mellitus prove therapeutic behavioral achain position bchain position insulin endogenous hormone produced insulin protein highly conserved across evolutionary time present mammals invertebrates insulininsulinlike growth factor signalling pathway iis extensively studied species including nematode worms egc elegans flies drosophila melanogaster mice mus musculus mechanisms action highly similar across type diabetes type diabetes marked loss pancreatic function though differing people affected diabetes referred diabetics many diabetics require exogenous source insulin keep blood sugar levels within safe target nicolae c paulescu succeeded developing aqueous pancreatic extract normalized diabetic dog published papers society biology paris centering successful effects pancreatic extract diabetic dogs research role pancreas food assimilation paulescu published august archives internationales de physiologie liège belgium initially way obtain insulin clinical use extract pancreas another creature animal glands obtainable waste product meatpacking industry insulin derived primarily cows eli lilly company pigs nordisk insulinlaboratorium making eight ounces purified insulin could require much two tons pig insulin sources effective humans highly similar human insulin three amino acid difference bovine insulin one amino acid difference initially lower preparation purity resulted allergic reactions presence noninsulin substances purity improved steadily since ultimately reaching purity thanks highpressure liquid chromatography hplc methods minor allergic reactions still occur occasionally even synthetic human insulin beginning biosynthetic human insulin manufactured clinical use genetic engineering techniques using recombinant dna technology genentech developed technique used produce first insulin humulin commercially market product eli lilly marketed humulin humulin first medication produced using modern genetic engineering techniques actual human dna inserted host cell e coli case host cells allowed grow reproduce normally due inserted human dna produce synthetic version human insulin manufacturers claim reduces presence many impurities however clinical preparations prepared insulins differ endogenous human insulin several important respects example absence cpeptide recent years shown systemic effects novo nordisk also developed genetically engineered insulin independently using yeast according survey international diabetes federation conducted access availability insulin member countries approximately insulin currently sold world recombinant biosynthetic human majority insulin used clinically today produced way although clinical experience provided conflicting evidence whether insulins less likely produce allergic reaction adverse reactions reported include loss warning signs patients may slip coma hypoglycemia convulsions memory lapse loss however international diabetes federations position statement clear stating overwhelming evidence prefer one species insulin another modern highly purified animal insulins remain perfectly acceptable since january insulins distributed us countries synthetic human insulins analogues special fda importation process required obtain bovine porcine derived insulin use us although may remaining stocks porcine insulin made lilly earlier porcine lente insulin also sold marketed brand name vetsulinsm us veterinary usage treatment companion animals type diabetes insulin production extremely low body requires exogenous insulin people type diabetes particularly high hemoglobin values may also require baseline rate insulin body desensitized level insulin produced basal insulin regulates bodys blood glucose mealtimes well overnight basal rate insulin action generally achieved via use intermediateacting insulin nph longacting insulin analog type diabetics may also achieved via continuous infusion rapidacting insulin using insulin pump approximately half persons daily insulin requirement administered basal insulin usually administered per day person eats food containing carbohydrates glucose insulin helps regulate bodys metabolism food prandial insulin also called mealtime bolus insulin designed bolus dose insulin prior meal regulate spike blood glucose occurs following meal dose prandial insulin may static may calculated patient using either current blood sugar planned carbohydrate intake calculation may also performed insulin pump patients using pump insulin regiments consist doses calculated manner considered intensive insulin prandial insulin usually administered minutes prior meal using rapidacting insulin regular insulin patients combination insulin may used contains nph long acting insulin rapidregular insulin provide basal insulin prandial several challenges involved use insulin clinical treatment medical preparations insulin never insulin water nothing else clinical insulins mixtures insulin plus substances including preservatives prevent protein spoiling denaturing rapidly delay absorption insulin adjust ph solution reduce reactions injection site slight variations human insulin molecule called insulin analogues technically insulin receptor ligands named technically insulin rather analogues retain hormones glucose management functionality absorption activity characteristics currently possible subcutaneously injected insulin proper either absorbed rapidly attempt mimic real beta cell insulin insulin lispro insulin aspart insulin glulisine steadily absorbed injection instead peak followed less rapid decline insulin action insulin detemir insulin glargine retaining insulins glucoselowering action human body however number metaanalyses including done cochrane collaboration germanys institute quality cost effectiveness health care sector iqwig released canadian agency drugs technology health also released shown unequivocal advantages clinical use insulin analogues conventional insulin commonly used types insulin includes insulin analogues aspart lispro glulisine begin work within minutes active hours insulins form hexamers delay entry blood active form analog insulins normal insulin activity newer varieties pending regulatory approval us designed work rapidly retain genetic structure regular human includes regular insulin begins working within minutes active includes nph insulin begins working hours active includes analogues glargine detemir begins working within hours continues active without major peaks dips hours although varies many includes analogues insulin glargine degludec begin working within minutes continues active greater includes combination either fastacting shortacting insulin longeracting insulin typically nph insulin combination products begin work shorteracting insulin minutes fastacting minutes shortacting remain active hours several variations different proportions mixed insulins eg novolog mix contains aspart protamine akin nph unlike many medicines insulin taken orally present time like nearly proteins introduced gastrointestinal tract reduced fragments single amino acid components whereupon activity lost research ways protect insulin digestive tract administered pill far entirely insulin usually taken subcutaneous injections singleuse syringes needles insulin pump repeateduse insulin pens needles people wish reduce repeated skin puncture insulin injections often use injection port conjunction use subcutaneous injections insulin designed mimic natural physiological cycle insulin secretion taking account various properties formulations used halflife onset action duration action many people rapid shortacting insulin product well intermediate longacting product used decrease amount injections per day insulin injections may combined injection therapy agonists cleansing injection site injection technique required ensure effective insulin insulin pumps reasonable solution advantages person better control background basal insulin dosage bolus doses calculated fractions unit calculators pump may help determining bolus infusion dosages limitations cost potential hypoglycemic hyperglycemic episodes catheter problems closed loop means controlling insulin delivery based current blood glucose levelscitation needed insulin pumps may like electrical injectors attached temporarily implanted catheter cannula achieve adequate glucose control conventional jet injection able appropriate indwelling catheters pose risk infection ulceration peoples may also develop lipodystrophy due infusion sets risks often minimized keeping infusion sites clean insulin pumps require care effort use one international unit insulin iu defined biological equivalent μg pure crystalline insulin first definition unit insulin amount required induce hypoglycemia rabbit set james collip university toronto course dependent size diet rabbits unit insulin set insulin committee university unit evolved eventually old usp insulin unit one unit u insulin set equal amount insulin required reduce concentration blood glucose fasting rabbit gd l moll chemical structure mass insulin known unit insulin defined mass pure crystalline insulin required obtain usp unit unit measurement used insulin therapy part international system units abbreviated si modern form metric system instead pharmacological international unit iu defined expert committee biological central problem requiring external insulin picking right dose insulin right timing physiological regulation blood glucose nondiabetic would best increased blood glucose levels meal stimulus prompt release insulin pancreas increased insulin level causes glucose absorption storage cells reduces glycogen glucose conversion reducing blood glucose levels reducing insulin release result blood glucose level rises somewhat eating within hour returns normal fasting level even best diabetic treatment synthetic human insulin even insulin analogs however administered falls far short normal glucose control complicating matters composition food eaten see glycemic index affects intestinal absorption rates glucose foods absorbed less rapidly amount glucose foods addition fats proteins cause delays absorption glucose carbohydrates eaten time well exercise reduces need insulin even factors remain since working muscle ability take glucose without help complex interacting factors principle impossible know certain much insulin type needed cover particular meal achieve reasonable blood glucose level within hour two eating nondiabetics beta cells routinely automatically manage continual glucose level monitoring insulin release decisions diabetic must based experience training ie direction physician pa places specialist diabetic educator specifically based individual experience person straightforward never done habit routine care however done reasonably well clinical practice example people diabetes require insulin drinking skim milk taking equivalent amount fat protein carbohydrate fluid form particular reaction skimmed milk different people diabetes amount whole milk likely cause still different reaction even person whole milk contains considerable fat skimmed milk much less continual balancing act people diabetes especially taking insulin people insulindependent diabetes typically require base level insulin basal insulin well shortacting insulin cover meals bolus also known mealtime prandial insulin maintaining basal rate bolus rate continuous balancing act people insulindependent diabetes must manage day normally achieved regular blood tests although continuous blood sugar testing equipment continuous glucose monitors cgms becoming available could help refine balancing act widespread usage becomes common longacting insulin used approximate basal secretion insulin pancreas varies course nphisophane lente ultralente glargine detemir may used purpose advantage nph low cost fact mix shortacting forms insulin thereby minimizing number injections must administered activity nph peak hours administration allowing bedtime dose balance tendency glucose rise dawn along smaller morning dose balance lower afternoon basal need possibly afternoon dose cover evening need disadvantage bedtime nph taken late enough near midnight place peak shortly dawn potential causing hypoglycemia one theoretical advantage glargine detemir need administered day although practice many people find neither lasts full hours administered time day well provided given time every day another advantage longacting insulins basal component insulin regimen providing minimum level insulin throughout day decoupled prandial bolus component providing mealtime coverage via ultrashortacting insulins regimens using nph regular insulin disadvantage dose adjustment affects basal prandial coverage glargine detemir significantly expensive nph lente ultralente mixed forms insulincitation needed shortacting insulin used simulate endogenous insulin surge produced anticipation eating regular insulin lispro aspart glulisine used purpose regular insulin given leadtime prior meal maximally effective minimize possibility hypoglycemia lispro aspart glulisine approved dosage first bite meal may even effective given completing meal shortacting insulin also used correct first described physicians typically refer slidingscale insulin ssi fast rapidacting insulin given subcutaneously typically meal times sometimes blood glucose threshold eg mmoll socalled slidingscale method widely taught although heavily sliding scale insulin ssi effective way managing longterm diabetes individuals residing nursing sliding scale insulin leads greater discomfort increased nursing sample regimen using insulin glargine insulin lispro pregnancy spontaneous hyperglycemia develop lead gestational diabetes mellitus gdm frequent pregnancy complication prevalence among pregnant women globally gestational diabetes mellitus gdm defined degree glucose intolerance developing initially recognized neutral protamine hagedorn nph insulin cornerstone insulin therapy pregnancy administered two four times per day women gdm pregnant women type diabetes mellitus frequently check blood glucose levels utilize glucose monitoring equipment use continuous insulin infusion rapidacting insulin analogue lispro aspart however number considerations go choosing regimen administering insulin patients managing gdm pregnant women guidelines crucial vary depending certain physiological interestingly sociocultural environment well current perinatal guidelines recommend low daily dose insulin take account womans physiological features frequency selfmonitoring importance using specialized insulin therapy planning based parameters like stated rather broad approach women preexisting diabetes highest levels insulin sensitivity early pregnancy close glucose monitoring required prevent hypoglycemia potentially result altered consciousness seizures maternal low birth weight newborns might also result hypoglycemia especially patients type diabetes frequently insulin sensitive persons type diabetes likely unaware hypoglycemic state close glucose monitoring essential weeks pregnancy women preexisting diabetes become insulin resistant insulin demands may fluctuate weekly need insulin may rise one pregnancy next therefore realistic expect higher needs glucose control subsequent pregnancies multiparous possibility using insulin attempt improve athletic performance suggested early winter olympics nagano japan reported peter sönksen july issue journal endocrinology question whether nondiabetic athletes could legally use insulin raised russian medical whether insulin would actually improve athletic performance unclear concerns use led international olympic committee ban use hormone nondiabetic athletes book game shadows reporters mark fainaruwada lance williams included allegations baseball player barry bonds used insulin well drugs apparent belief would increase effectiveness growth hormone alleged bonds eventually testified front federal grand jury part government investigation bodybuilders particular claimed using exogenous insulin drugs belief increase muscle mass bodybuilders described injecting iu regular synthetic insulin eating sugary report suggested insulin sometimes used combination anabolic steroids growth hormone gh athletes exposing potential harm large doses gh insulin abuse mentioned possible factor deaths bodybuilders ghent wakefield rich insulin human growth hormone hgh insulinlike growth factor selfadministered looking increase muscle mass beyond scope offered anabolic steroids alone rationale since insulin hgh act synergistically promote growth since primary mediator musculoskeletal growth stacking insulin hgh offer synergistic growth effect skeletal muscle theory supported recent years toplevel bodybuilders whose competition weight excess lb kg muscle larger competitors past even lower levels body fatcitation needed exogenous insulin significantly boosts rate glucose metabolism training athletes along substantial increases peak insulin thought enhance performance increasing protein synthesis reducing protein catabolism facilitating transfer certain amino acids human skeletal muscle insulintreated athletes perceived lean body mass physiological hyperinsulinemia human skeletal muscle improves activity amino acid transport turn promotes protein insulin stimulates transport amino acids cells also controls glucose metabolism decreases lipolysis increases lipogenesis bodybuilders athletes use rhgh conjunction offset negative effect maximizing protein synthesis athletes extrapolated physiology diabetic patient sporting arena interested suppression proteolysis insulin administration found protein anabolic insulinresistant state chronic renal inhibits proteolysis administered along amino acids enhances net protein synthesis exogenous insulin injection creates invivo hyperinsulinemic clamp boosting muscle glycogen recovery phases intense exercise power strength stamina expected increase result might also speed healing process intense physical activity second insulin expected increase muscle mass preventing breakdown muscle protein consumed along high carbprotein diet although limited number studies suggest insulin medication abused pharmacological treatment boost strength performance young healthy people athletes recent assessment research argues applicable small group drugnaïve abuse exogenous insulin carries attendant risk hypoglycemic coma death amount used excess required handle ingested carbohydrate acute risks include brain damage paralysis death symptoms may include dizziness weakness trembling palpitations seizures confusion headache drowsiness coma diaphoresis nausea persons overdoses referred medical assessment treatment may last hours data us national poison data system indicates insulin cases reported poison centers unintentional result therapeutic error another cases intentional may reflect attempted suicide abuse criminal intent secondary gain unknown hypoglycemia induced exogenous insulin chemically detected examining ratio insulin cpeptide peripheral suggested type approach could used detect exogenous insulin abuse insulin often measured serum plasma blood order monitor therapy people diabetic confirm diagnosis poisoning hospitalized persons assist medicolegal investigation suspicious death interpretation resulting insulin concentrations complex given numerous types insulin available various routes administration presence antiinsulin antibodies insulindependent diabetics ex vivo instability drug potential confounding factors include wideranging crossreactivity commercial insulin immunoassays biosynthetic insulin analogs use highdose intravenous insulin antidote antihypertensive drug dosage postmortem redistribution insulin within body use chromatographic technique insulin assay may preferable immunoassay circumstances avoid issue crossreactivity affecting quantitative result also assist identifying specific type insulin combination therapy insulin antidiabetic drugs appears beneficial people diabetic still residual insulin secretory combination insulin therapy sulfonylurea effective insulin alone treating people type diabetes secondary failure oral drugs leading better glucose profiles andor decreased insulin united states unit price insulin increased steadily rose threefold costs high per concerns raised pharmaceutical companies working together increase january lawmakers united states house representatives sent letters insulin manufacturers eli lilly co sanofi novo nordisk asking explanations rapidly raising insulin prices annual cost insulin people type diabetes us almost doubled period people us pay two six times rest world including canada brand name prescription medicine according international federation health plans canada like many industrialized countries price controls cost california july approved budget allocates million state create insulin closetocost insulin medications supplied free charge people use manage diabetes national health services countries united march fda changed regulatory pathway approval new insulin insulin regulated biologic rather changed status gives fda flexibility approval july fda approved insulin glargineyfgn semglee biosimilar product contains long acting analog insulin insulin glargineyfgn interchangeable less expensive reference product insulin glargine lantus approved fda requires new insulin products inferior existing insulin products respect reduction hemoglobin us food drug administration fda approved use exubera first inhalable withdrawn market maker third quarter due lack acceptance inhaled insulin claimed similar efficacy injected insulin terms controlling glucose levels blood halflife currently inhaled insulin short acting typically taken meals injection longacting insulin night often still people switched injected inhaled insulin significant difference observed levels three months accurate dosing particular problem although people showed significant weight gain pulmonary function decline length trial compared following commercial launch united kingdom july recommended national institute health clinical excellence routine use except cases proven injection phobia diagnosed psychiatrist january worlds largest insulin manufacturer novo nordisk also announced company discontinuing development companys version inhalable insulin known aerx idms inhaled insulin similarly eli lilly company ended efforts develop inhaled air insulin march afrezza developed mannkind authorized fda june use adults type type ii diabetes label restriction limiting use also asthma active lung cancer chronic obstructive pulmonary rapidacting inhaled insulin component drugdevice combination solution used start every meal employs technosphere technology appears practical delivery method dosing flexibility new inhaled insulin formulation thumbsized inhaler improved dosage flexibility used deliver inhalable insulin includes powderdissolved recombinant human insulin fumaryl diketopiperazine technosphere insulin quickly absorbed lung surface inhalation within hours inhalation powder fumaryl virtually eliminated healthy peoples lungs comparison exubera inhaled insulin still present lungs hours however since serum antibody levels reported increase without substantial clinical changes acute bronchospasm asthmatic copd patients along significant reduction diffusing lung capacity carbon monoxide comparison subcutaneous insulin reported usage afrezza given fda approval warning risk evaluation mitigation several methods transdermal delivery insulin pulsatile insulin uses microjets pulse insulin person mimicking physiological secretions insulin jet injection different insulin delivery peaks durations compared needle injection diabetics may prefer jet injectors hypodermic electricity using ultrasound found make skin temporarily porous insulin administration aspect remains experimental blood glucose test aspect wrist appliances commercially available researchers produced watchlike device tests blood glucose levels skin administers corrective doses insulin pores skin similar device relying skinpenetrating microneedles animal testing stage last couple years use chemical enhancers electrical devices microneedle devices shown tremendous promise improving penetration insulin compared passive transport via skin transdermal insulin delivery shows patientfriendly minimally invasive approach daily diabetes care conventional hypodermic injection however additional research necessary address issues longterm use delivery efficiency reliability well side effects involving inflammation insulin delivered central nervous system via intranasal route little systemic uptake associated peripheral side effects demonstrated intranasally delivered insulin rapidly accumulates csf fluid indicating effective transport brain accumulation thought occur along olfactory nearby routes although numerous studies published encouraging results study still conducted comprehend longterm impacts order begin successful clinical basic appeal hypoglycemic agents mouth people would prefer pill oral liquid injection however insulin peptide hormone digested stomach gut order effective controlling blood sugar taken orally current form potential market oral form insulin assumed enormous thus many laboratories attempted devise ways moving enough intact insulin gut portal vein measurable effect blood number derivatization formulation strategies currently pursued attempt develop orally available many approaches employ nanoparticle delivery several tested clinical another improvement would transplantation pancreas beta cell avoid periodic insulin administration would result selfregulating insulin source transplantation entire pancreas individual organ difficult relatively uncommon often performed conjunction liver kidney transplant although done also possible transplantation pancreatic beta cells however islet transplants highly experimental many years researchers alberta canada developed techniques high initial success rate one group nearly half got islet cell transplant insulinfree one year operation end second year number drops one seven however researchers university illinois chicago uic slightly modified edmonton protocol procedure islet cell transplantation achieved insulin independence diabetic people fewer betterfunctioning pancreatic islet longerterm studies needed validate whether improves rate insulinindependence beta cell transplant may become practical near future additionally researchers explored possibility transplanting genetically engineered nonbeta cells secrete clinically testable results far realization time several nontransplant methods automatic insulin delivery developed research labs none close clinical approval